Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Ankylosing Spondylitis

Study Supports Bimekizumab for Nonradiographic Axial Spondyloarthritis

Brian Park, PharmD

January 21, 2022

The ongoing phase 3 BE MOBILE 1 study compared the efficacy and safety of bimekizumab to placebo in adults with active nr-axSpA.

General Medicine

Influenza Vaccination Reduces Risk for Critical Illness in Children

Brian Park, PharmD

January 21, 2022

During a season predominated by 2 vaccine-mismatched viruses, vaccination was estimated to reduce the risk of life-threatening influenza illness by 75%.

General Medicine

Study Supports Coadministration of Pneumococcal Vaccine and Pfizer-BioNTech COVID-19 Vaccine

Brian Park, PharmD

January 19, 2022

The randomized, double-blind study recruited adults from the phase 3 Pfizer-BioNTech COVID-19 vaccine trial.

Inflammatory Myopathy

Antisense Oligonucleotide Fast-Tracked for Myotubular and Centronuclear Myopathies

Brian Park, PharmD

January 18, 2022

The Company is currently evaluating DYN101 in the phase 1/2 UNITE-CNM trial in patients 16 years of age and older with CNM caused by mutations in the MTM1 or DNM2 gene.

Gout

Horizon Seeks Approval of Pegloticase Plus Methotrexate for Uncontrolled Gout

Brian Park, PharmD

January 14, 2022

The sBLA submission is supported by data from the phase 4 MIRROR trial.

General Rheumatology

Novel Immunomodulator Gets Orphan Drug Status for Sarcoidosis

Brian Park, PharmD

January 13, 2022

Results from a phase 1/2 showed that ATYR1923 was safe and well tolerated.

General Medicine

FDA Shortens Booster Dose Interval for Moderna COVID-19 Vaccine

Brian Park, PharmD

January 13, 2022

The Moderna booster dose is authorized for individuals 18 years of age and older.

General Medicine

CDC Shortens Recommended COVID-19 Isolation, Quarantine Period

Brian Park, PharmD

January 6, 2022

The CDC has also updated the recommended quarantine period for individuals exposed to someone with COVID-19.

Osteoarthritis

Gene Therapy Gets Fast Track Status for Pain Associated With Knee Osteoarthritis

Brian Park, PharmD

January 4, 2022

XT-150 is a locally injectable non-viral therapy expressing interleukin (IL)-10v, a proprietary modified variant of IL-10.

Pediatric Rheumatology

Secukinumab Approved for Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis

Brian Park, PharmD

December 28, 2021

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.

Next post in Pediatric Rheumatology